(Health Korea News / Lee Si-woo) Hanmi Pharmaceuticals (CEO Park Jae-hyeon) announced the clinical trial of ‘Amosartan Family’, Hanmi’s representative new combination drug for hypertension treatment, and ‘Rosuzet’, a combination new drug for dyslipidemia, at the industry-academia session of the Korean Cardiology Association’s fall academic conference. It was announced on the 8th that a presentation on usefulness was made based on appropriate evidence.
This session, held at the Grand Walkerhill Seoul Hotel on the 18th of last month, was conducted for specialists in the fields of cardiology and circulatory medicine nationwide. Professor Young-Geun Ahn of Chonnam National University and Professor Seok-Min Kang of Yonsei University College of Medicine served as moderators, and Professor Seong-Hee Shin of Inha Medical University and Professor Ki-Hong Choi of Sungkyunkwan University College of Medicine each presented presentations.
The first speaker, Professor Shin Seong-hee, focused on the benefits of active blood pressure control recommended by various domestic and international guidelines and the importance of the role of combination drugs in treating high blood pressure.
Professor Shin said, “In the recently announced ESC (European Society of Cardiology) 2024 guidelines, the diagnostic criteria for normal blood pressure have been strengthened to 120/70, emphasizing the importance of strict blood pressure control, which has the effect of improving left ventricular hypertrophy and preventing cardiovascular disease. “Combination therapy is essential for active blood pressure control, and the role of three-drug combination therapy for hypertension treatment has recently been growing,” he said.
Professor Shin continued, “Amosartan Plus, a three-drug combination drug for hypertension that adds chlorthalidone to Amosartan, can be considered as an option to increase patient compliance and treatment effectiveness with just one pill. ) is a diuretic recommended first in domestic and international guidelines, and there are no significant differences in adverse reactions from HCTZ.”
Chairperson Professor Ahn Young-geun said, “Losartan is a drug with the largest number of approved indications at home and abroad among the ARB class, including hypertension, heart failure, stroke prevention, and diabetic nephropathy, and the Amosartan family, which is a Losartan-based product, has evidence in combination therapy for patients with various underlying hypertension conditions. “It could become a central option,” he said.
Professor Kihong Choi, the second speaker, emphasized the clinical basis for Rosuzet by presenting the results of the RACING Trial and its sub-analyses, which contributed to a paradigm shift in dyslipidemia treatment.
Professor Choi said, “It is now public knowledge that the lower the LDL-C level, the greater the clinical benefit, but the control rate is low due to the lack of change in treatment strategy due to therapeutic inertia in patients who have not yet reached the treatment goal. “It is staying in the 50% range,” he said. “Rosujet is a high-intensity statin monotherapy (rosuvastatin 20mg) for domestic patients with arteriosclerotic cardiovascular disease through the RACING Trial and sub-studies. By confirming the CV outcome non-inferiority, excellent LDL-C goal attainment rate, and tolerability of moderate-intensity statin/ezetimibe (Rosujet 10/10mg) compared to other drugs, it was confirmed that it is a treatment option that can break the therapeutic inertia of statin monotherapy. “He emphasized.
Professor Seok-min Kang, who served as moderator, said, “The reason Rosuzet was able to become the No. 1 outpatient prescription drug product* in Korea was an achievement possible because it established clinical evidence in various patient groups in Korea,” adding, “This year, statin/ezetimibe combination therapy “As the basis for primary prevention of cardiovascular disease has been established, the paradigm shift in dyslipidemia treatment strategies will further accelerate,” he predicted.
Myeong-hee Park, Executive Director of Hanmi Pharmaceutical’s Domestic Business Division, said, “Through this industry-academia session, we once again conveyed the clinical benefits of Amosartan, which celebrates its 15th anniversary this year, and Rosuzet, the No. 1 outpatient prescription drug in Korea, to cardiologists and circulatory medicine specialists to treat hypertension. “We were able to introduce Hanmi Pharmaceutical’s diverse lineup of treatments in the treatment of hypertension and dyslipidemia,” he said. “Through continuous research and development, we are establishing a paradigm for the treatment of hypertension and dyslipidemia.” “We will lead the way and continue to pursue evidence-based marketing in the future.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
